Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428439 | 0.93 | BMP1 (0.61) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL6430177 | 0.93 | BMP1 (0.70) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL6428568 | 0.90 | BMP1 (0.70) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL6430368 | 0.89 | BMP1 (0.56) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL5404341 | 0.87 | BMP1 (0.53) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL6428708 | 0.86 | BMP1 (0.54) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL14502823 | 0.85 | BMP1 (0.51) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL5403103 | 0.83 | BMP1 (0.64) | BMP1MMP2MMP3 | |
| SCHEMBL5405413 | 0.83 | BMP1 (0.49) | BMP1MMP2MMP3MMP9 | |
| SCHEMBL5411045 | 0.82 | BMP1 (0.51) | BMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | DATTA USA (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6716861-B2 | HETEROCYCLIC 1,2,4-OXADIAZOLE OR OXAZOLE RING CONTAINING PROPANOHYDROXAMIC ACIDS USEFUL AS ANTISCARRING AGENT | PFIZER, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1343771-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | PFIZER, INC | 2002-10-17 | — | — | US | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | BMP1 166/4885MMP2 16/4885MMP3 8/4885 |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | ALPI, TIMP3, MMP1 | BMP1 376/4885MMP2 22/4885MMP3 9/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | BMP1 79/4885MMP2 11/4885MMP3 18/4885 |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | ALPI, TIMP3, MMP1 | BMP1 376/4885MMP2 22/4885MMP3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.